

Air Force Institute for Operational Health



DoD-GEIS Influenza Surveillance and Response Program

Information Only

Defense Health Board
03 May 2007





Background



- DoD Global Influenza Surveillance Program
 - DoD-GEIS Global, Laboratory-Based Influenza Surveillance Program
 - Sentinel site influenza surveillance
 - Managed at AFIOH, Brooks City-Base, TX
 - Population-based febrile respiratory illness surveillance
 - Managed at NHRC, San Diego, CA



Surveillance Sites



U.S. AIR FORCE

Routine Surveillance

- Sentinel sites
 - 65 Global Sites

Expansion efforts

Initial discussions for participation

Hungary Israel

Brazil Poland


South Africa Georgia

Romania Bulgaria



Participation







JAFIOH *



U.S. AIR FORCE

DoD Global Influenza Surveillance Program Surveillance at AFIOH

Public Health QUICK SHEET

for the Influenza Surveillance Program

- Ensure all Primary Care Manager (clinic) teams are supplied with the "Influenza Surveillance Questionnaire" (https://gumbo.brooks.af.mil/ pestilence/influenza).
- Ensure Primary Care Manager (clinic) teams are supplied with collection kits (contact AFIOH lab: Ina Smith @ DSN 240-1680).
- 3. Pick up questionnaires weekly from Primary Care Manager teams.
- Ensure 6-10 specimens meeting the ILI case definition are submitted each week. Do not submit specimens unless they meet the ILI case definition.
- Enter all questionnaires online at (https://gumbo.brooks.af.mil/ pestilence/influenza).
- Enter all lab-confirmed positive influenza specimens into the servicespecific Reportable Medical Events System (i.e., AFRESSII).
- Recommend staff training at least 3 times/yr to ensure importance of influenza surveillance. A training presentation is available at https:// gumbo.brooks.af.mil/pestilence/influenza.
- Notify us at influenza@brooks.af.mil if you suspect an influenza outbreak at your base. It is important that outbreaks among the military communities are tracked so threats to our military forces can be mitigated. If assistance is needed, we are happy to support you as needed-contact Angie Owens or Matt Johns at DSN 240-3471.
- Contact us at any time!! (210) 536-3471; DSN 240-3471
 E-mail: influenza@brooks.af.mil
 Website: https://gumbo.brooks.af.mil/pestilence/influenza



Public

The Protocol for yo

influence surveillance in the Staff area sentinel other in previously due to it social celetions among leastlens and it

What specimens are collected

Only submit specimens from partimenting the influence the times (U) of authorize.

Ferrer 1: 100.5²7/38²C and or equi 8362 straigh or one throat of 432

How will have need the CT

positiva influence conscion a vasably to for an appropriate public health sportes.







U.S. AIR FORCE

AIR FORCE INSTITUTE FOR OPERATIONAL HEALTH	DoD Global Influenza Surveillance Program											
(AFIOH) BROOKS CITY-BASE, TX	Influenza Surveillance Questionnaire											
IMPORTANT	Installation/DMIS Code: Fort Bliss Date of Clinic Visit											
Specimen Submission	PRIVACY ACT STATEMENT: The social security number is required to facilitie documentation of health care re- ceived and patient follow-up. The privacy use of this intervention is to aid in presentine health and constructionis de-											
***8-10 specimens/week	ease control programs. The requested information is voluntary.											
	Patient Information PLEASE PRINT LEGIBLY											
To Participate:	Patient Name: Date of Birth:											
This questionnaire MUST be completed (in full) for each specimen submitted.	Patient FMP Sponsor SSN Gender: Male Female											
2) Patent MUST meet the influ-	Sponsor's (military member) Work Phone ()DSN #											
enza-ika šiness (LI) case defi- nitor:	If taken at home, Highest Temp Recorded: Cale Taken											
	Bympfoms: Please select NA (Not Applicable) if the presence of symptoms cannot be determined.											
ILI Case Definition	Sore Throat: Yes / No / NA Cough: Yes / No / NA Vamiting: Yes / No / NA											
 Fever ≥100.5°F (38°C), oral or equivalent 	Chest Pain: Yes / No / NA Fatigue: Yes / No / NA Conjunctivitis: Yes / No / NA											
AND	Headache: Yes / No / NA Chills: Yes / No / NA Ear Ache: Yes / No / NA											
Cough and/or Sore Throat	Diamhea: Yes / No / NA Body Aches: Yes / No / NA Stiffness: Yes / No / NA											
	Dyspnea: Yes / No / NA Runny Nose: Yes / No / NA Shus Congestion: Yes / No / NA											
Quectionnaire Submission	Old the patient travel recently (past 14 days)? Yes No Unknown											
https://gumbo.brooks.af.mil/ pestilence/influenza	If YES, Where? When? When?											
1) This questionnaire should be												
entered and submitted online.	Has the patient received the influenza vaccine this season? Yes: No: Unknown											
 Additional questionnairee can be downloaded from the AFICH Influenza website. 	If YES, list date Estimated Date: 4 Set helf or 2nd helf of Max.											
3) When ordering a test in CHCS,	Type:injection (Fiu Shot)Nasai Spray (FiuMist)											
annotate in the Remarks sec- tion "Flu Surveillance".	Location:Millary facilityCivilian facility											
Make a copy of this questionnaire for administrative purposes:	Clinical Information PRINT LEGIBLY											
To reache discrepant infor-	Fever (2100.5°F / 38°C, oral or equivalent) Temperature =											
mation	AND (check the symptom/s) aCough or bSore throat (<72 hours duration)											
 For celeboling results and entering them into the Report- 	When did symptoms start? Date:											
able Medical Events System (PMES)	Hospifalized? Yes / No If YES, how long (hrs)? Hospifal Name?											
	Patient put on Quarters? Yes / No If YES, how long (hrs)?											
Questions?	Physician (name and number):											
Please e-mail:	Name Contact Phone Number											
Influenza@brooks.af.mii	Surveillance information (to be completed by public health staff) PRINT LEGIBLY											
	* Entered "influenza Surveillance" in CHCS Remarks section? Yes / No											
	*Questionnaire entered online (htps://gunbo.brosks.af.milipedilenceInfluenza) dafe:											
	Keep questionnaires for assistance in entering information into service's "Reportable Medical Events System" (RMCS).											

Nasal Wash-Procedural Guidelines

- 13 Have patient blow their note into a time to dear excess mucus.
- E.) Tuck bib into outlent's shirt coller.
- Unicas pre-filled saline sintings and specimen collection container. Small the seal on the oringe brigenth expressing a small amount of saline into the do of the hub.
- 4) Have outlent filt their head back so ther are able to look directir at the ceiling while ther hold the speckren collection container up to their chin area.







- 5.) Succurage outlant to not ovulow sales by suring "Ka Ka Ka" while sales is economic into their
- 4.) Gently express E-4 mil. of sterile sales into the sedent's right nostril. Salme will drain back into the back of the resoutherves.
- 7.) After a few seconds, have the collect less their head for exough forward so the saline will drain into the toedmen collection container. Repeat for second mostrif.
- 1) Offer patient a facial figure or have there use the bib to whos away expect soline from their face.
- 153 PSx the contexts with the Viral Transport Medium (VTPS) included in the kill, Sending the rim of the can will help in pouring the contents into the YT71 habe.





Step 11

11.) Flace specimen in the bisheared bag included in the lift and forward to laboratory for captaging and shipment to APICH. In order to maintain colonial study for diagnostics, please be sure to ready the spedmen for immediate utilizant.

Storing, Packing and Shipping Josephan stability

Refrigerated: Up to 4 dars in VTFI; ship on gel packs.

Frozen 1-70°C): Greater than 76 hours; ship on dry ke. Flesse contact ARCHI if dry ice is not evaluable at your site. Viral transport appolles may be prolated by emailing our Customer Service department at epitab.hels@brooks.afmill

or by calling \$10-536-6379 (DSN: \$40-6379). Please ship to: FedEx number 1541-0380-0

AFRONDOS 2710 Louis Bouer Orine, Building 930 San Antonio, TX 78225-5-132

For additional packing and efficient details, please one the AFCH-SDS Lab website: https://c.einc.or/scombines/sld-bas-Acht-pack-http://db.de-CTS_04860_

Please see the video demonstration at http://www.airforcemedicine.afms.mil/flu

For other information please see our website at: Jastinnoa/Influenza/

-Important-


For Military Treatment Facilities Please remember to order "Respiratory Viral Culture(EPI)" in CHCS for respiratory surveillance.







U.S. AIR FORCE



Good Morning,


The DoD Global Influenza Surveillance Program at the Air Force Institute for Operational Health (AFIOH) reviews influenza-like illness (ILI) activity at US military sites each week. We noticed an increase in ILI activity at your site (see graph below). This is a significant increase that is notably higher than previous weeks. I understand it is currently the influenza season, but have you been made aware of any other factors that may be the cause for this spike? If so, please respond back to us within the next 8 hours.

Possible action items in response to the spike:

If your site experiences a respiratory spike such as this, we would appreciate if you could have your clinic/hospital staff:

- Contact the AFIOH laboratory at (210) 536-8383; DSN 240 for supplies and/or FedEx account number to ship specimens
- Collect a sample (6-10 per week) of specimens from patients meeting the ILI case definition (fever = 100.5°F and a cough or sore throat)
- Immediately ship to: AFIOH/SDE 2730 Louis Bauer Drive, Bldg 930 Brooks City-Base TX 78235-5132

This will help identify the agent if it is a respiratory outbreak and help to mitigate it as soon as possible. We test the specimens for a panel of respiratory viruses and report the results back to both the public health office (via electronic e-mail) and the provider (via CHCS). See the attached material for more information regarding our program. If you have any questions, you can contact us at influenza@brooks.af.mil.







Routine Surveillance

- Educate
- Provide Supplies
- Monitor influenza-like illness (ILI)
- Routine communication
 - ILI status
 - Issues













Results













Products



U.S. AIR FORCE





U.S. AIR FORCE

Product_{Pop} 5



DoD Global Influenza Surveillance Program: Influenza Surveillance at AFIOH

DoD Global Influenza Surveillance Program Background

This program was established by the Global Emerging Infections Surveillance and Response System (GEIS) in 1997. The surveillance network includes the Air Force (global influenza surveillance established in 1976), the Navy (recruit adenovirus Medical Research Unit Armed Forces Research

DoD Global Influenza Surveillance Program: Influenza Surveillance at AFIOH

n ILI. LRMC has identified at least

rce Navy Army and Coast Guard

t the time of this report, 308 of the Based on the questionnaires:

ese 28% (60 of 212) had influenza

ter-Detachment INMRClairobi, Kenya).

DoD Global Influenza Surveillance Program: Influenza Surveillance at AFIOH Page 3 Influenza-like Illness (ILI) Overview

ILI activity among overall DoD MTFs is currently >1 standard deviation (SD) below the mean for Week 07 (presented in Graph

Map: Locations of sites submitting respiratory specimen

DoD Global Influenza Surveillance Program: Influenza Surveillance at AFIOH

fluenza vaccine (17 of 81) received the vaccine; below the mean. Note: at this time.

talized and 25 (31%) were placed

n surrounding countries an AFIOH forward lab. MC will forward all origi-l as record-specific data OH surveillance protocol

surveillance. Efforts ex-

Force as the Executive neficiaries at 46 sentinel

DoD overseas medical on and Preventive Medi-

AIR FORCE INSTITUTE FOR OPERATIONAL HEALTH

Influenza Threat Level:

Phase 3 Goal: Ensure rapid characterization of the new virus sub-type, & early detection, notification & response to additional cases.

- No current evidence of HPA H5N1 within North, Central, or South America.
- The current regional position includes much of Asia, the Middle East, Europe, and por-tions of Africa.

Total Specimens Collected . Collected in Week 07: 53 • 06-07 Seasonal Year: 1,232

Influenza patients by AGE

Percent of Total Flus 0-5: 12% (n=36) 6-9: 22% (n=66)

10-18: 02% (n=06) 19-24: 06% (n=17) 25-44: 14% (n=42)

45-64: 04% (n=12)

Unk*: 40% (n=119) *Unknown gathered from non-DoD beneficiaries

Influenza patients by FMP Percent of Total Flus

AD: 16% (n=50) Spouse: 07% (n=22) 39% (n=122)

- **Specimens Collected**
- 70% of total specimens
- · 231 influenza-positive - 73% of total flu positives

Overall Laboratory Surveillance 2

National & International 4 Program Overview 5

DoD Global Influenza Surveillance Program: Influenza Surveillance at AFIOH

Overall Laboratory Surveillance at AFIOH

Influenza (01 Oct - Present)

Week 07

316 influenza isolates

266 Influenza A; 50 Influenza B

26% of total specimens were positive for influenza: 84.2% influenza A; 15.8% influenza B

Influenza A

Influenza B A (H1): 217 B (Yamagata): 2 A (H3): 37 B (Victoria): 27 B/not subtyped: 21 A/not subtyped: 12

11-17 February 2007

Locations of Lab-confirmed Influenza



Human Avian Influenza (H5N1) Update

CY 2007: 11 cases, 9 of 11 fatal, confirmed in Egypt, Indonesia, and Nigeria. Since CY 2003, 274 highly pathogenic (HP) H5N1 human cases (61% fatality rate) have been confirmed in Azerbaijan, Cambodia, China, Djibouti, Egypt, Indonesia, Iraq, Nigeria, Thailand Turkey, and Viet Nam (19 Feb 2007, WHO)

Click on the following links for updates regarding human HP-H5N1.

- · World Health Organization (WHO)
- Centers for Disease Control and Prevention (CDC)
- Global Emerging Infections System (GEIS)

Influenza Outbreaks / News

AFIOH and PACOM partners discussing increased surveillance capabilities during regional military exercises. AFIOH continues to support such activities with surveillance instruments, specimen collection/shipping supplies, and epidemiology support.

- Storage of specimens prior to shipping: Remind staff to store specimens in a -70°C freezer or a regular refrigerator prior to shipping (-20°C is not acceptable). Ship at least twice weeklyl

This report summarizes the status of all respiratory viral cultures processed at the AFIOH laboratory For more background information, please see last page of this report.




Influenza Surveillance Questionnaire Overview

35% (420/1.193) were positive for a

hogens identified include: 3% (n=37) % (n=14) were enterovirus, and 19



IAVY: Overall ILI Activity



T GUARD: Overall ILI Activity



is been analyzed as drift variants ope. Both specimens were submit

ping Results by Week and Year offuenza Season 2005-2006



's influenza surveillance summaries.

ek 06. Of the specimens tested this e influenza B (see CDC map below).

fluenza positive specimens tested for

of collecting 6-10 speci-throat) and completing entinel Site Surveillance Regional Medical Center aracterized. These sites involvement in the DoD-

ra. adenovirus, enterovidays before a negative procedures.

in this report, visit our nation for sentinel sites

BEIS organizations.

a Surveillance Map







Products



Active Duty Influenza Immunization Status

Immunization Data collected by AFCITA

Data Status as of: 23 Mar 2007 06:36

Notes: # Required counts the active duty AF personnel assigned to each base - excluding IMAs; If someone is both a student and in a GSU, they are counted only once in the student category, # Current only considers shots given on or after 1 July 2006

		Regular					Student					GSU					Total				
MAJCOM	Base	Req	lmm	Exempt	Nbr Curr	% Curr	Req	lmm	Exempt	Nbr Curr	% Curr	Req	lmm	Exempt	Nbr Curr	% Curr	Req	lmm	Exempt	Nbr Curr	% Curr
ACC	BARK	5,332	5,296	17	5,313	99.6%	207	201	1	202	97.6%	130	118	0	118	90.8%	5,669	5,615	18	5,633	99.4%
ACC	BEAL	3,225	3,180	8	3,188	98.9%	16	16	0	16	100.0%	9	3	0	3	33.3%	3,250	3,199	8	3,207	98.7%
ACC	CANN	2,839	2,802	7	2,809	98.9%	16	13	0	13	81.3%	7	0	0	0	0.0%	2,862	2,815	7	2,822	98.6%
ACC	DAVI	5,950	5,855	11	5,866	98.6%	72	69	0	69	95.8%	305	241	0	241	79.0%	6,327	6,165	11	6,176	97.6%
ACC	DYES	4,863	4,744	11	4,755	97.8%	83	74	0	74	89.2%	327	183	0	183	56.0%	5,273	5,001	11	5,012	95.1%
ACC	ELLS	3,027	2,970	3	2,973	98.2%	16	14	0	14	87.5%	0	_	0	0		3,043	2,984	3	2,987	98.2%
ACC	HOLL	3,243	3,187	9	3,196	98.6%	7	7	0	7	100.0%	65	54	0	54	83.1%	3,315	3,248	9	3,257	98.3%
ACC	LANG	8,072	7,832	30	7,862	97.4%	71	41	0	41	57.7%	453	212	1	213	47.0%	8,596	8,085	31	8,116	94.4%
ACC	MEAD	2,088	2,045	10	2,055	98.4%	40	40	0	40	100.0%	24	16	0	16	66.7%	2,152	2,101	10	2,111	98.1%
ACC	MINO	4,425	4,377	17	4,394	99.3%	13	13	0	13	100.0%	0	0	0	0		4,438	4,390	17	4,407	99.3%
ACC	MOOD	3,367	3,312	10	3,322	98.7%	54	43	0	43	79.6%	94	69	0	69	73.4%	3,515	3,424	10	3,434	97.7%
ACC	MOUN	4,068	3,988	12	4,000	98.3%	11	11	0	11	100.0%	25	8	0	8	32.0%	4,104	4,007	12	4,019	97.9%
ACC	NELL	7,057	6,833	20	6,853	97.1%	49	39	0		79.6%	1,003	941	4	945	94.2%	8,109	7,813	24	7,837	96.6%
ACC	OFFU	5,646	5,503	7	5,510		337	307	0	307	91.1%	116	69	0	69	59.5%	6,099	5,879	7	5,886	
ACC	SEYM	4,050	3,944	9	3,953	97.6%	125	97	0	97	77.6%	46	22			47.8%	4,221	4,063	9		96.5%
ACC	SHAW	4,850	4,779	8	4,787	98.7%	102	76			74.5%	999	921	3		92.5%	5,951	5,776	11	5,787	97.2%
ACC	WHIT	3,232	3,224	3	3,227	99.8%	116	115	0		99.1%	50	48	0		96.0%	3,398	3,387	3		
		75,334	73,871	192	74,063	98.3%	1,335	1,176	1	1,177	88.2%	3,653	2,905	8	2,913	79.7%	80,322	77,952	201	78,153	97.3%
AETC	ALTU	1,470	1,445	13	1,458	99.2%	131	131	0	131	100.0%	4	3	0	3	75.0%	1,605	1,579	13	1,592	99.2%
AETC	COLU	845	829	11	840	99.4%	429	419	0	419	97.7%	147	104	1	105	71.4%	1,421	1,352	12	1,364	96.0%
AETC	GOOD	1,139	1,123	4	1,127	98.9%	715	690	1	691	96.6%	85	35	2	37	43.5%	1,939	1,848	7	1,855	95.7%
AETC	KEES	2,806	2,772	26	2,798	99.7%	1,415	1,383	1	1,384	97.8%	57	34	1	35	61.4%	4,278	4,189	28	4,217	98.6%
AETC	LACK	8,388	8,118	26	8,144	97.1%	2,663	2,349	0	2,349	88.2%	434	295	5	300	69.1%	11,485	10,762	31	10,793	94.0%
AETO	LAUC	050	044	- 1	OAE	OO 10/	400	400	1	400	OO 40/	Ω	n	n	n		1 240	1 222	n	1 225	വര വര/





Period of Review:

01 October 2006 – 13 April 2007

Fully Vaccinated

Vaccination date >14 days prior to clinic visit date


- Patients with vaccination date prior to August classified as unvaccinated
- Vaccination data gathered from Defense Enrollment Eligibility Reporting System (DEERS) and Influenza surveillance questionnaire





- Culture and/or PCR-confirmed influenza was observed in 19.4% (540 of 2,784) of the total respiratory samples submitted.
- ➤ Of these, 21.7% (117 of 540) had history of influenza vaccination during the 2006-2007 season.


64.1% (75 of 117) patients received the vaccine >14 days prior to the co








- Key influenza A/H3 isolates exhibited a R142G mutation, which has been characterized as a potential key contributor to the antigenicity of these strains.
- A small percentage of the isolates conferred mutations at several other of the reported antigenic sites.







Based on sequence analysis, a vast majority of the A/H1 isolates were homologous to the vaccine's New Caledonia component. However, there were a few divergent strains (Clade 2-like). Isolates from Clade 2 were obtained from CONUS.



Influenza A (H1N1) Field Isolates
HA1 HA Phylogenetic Analysis
2006/07 Season

Clade 1 isolates are from U.S. and Antarctica

HA is genetically similar to A/New Caledonia vaccine strain (red box).





Conclusions:

Of patients participating in the DoD Influenza Surveillance Program, 64% who had a history of influenza vaccination contracted an influenza infection >14 days post-vaccination.

Numerous influenza A isolates appeared to show certain genetic changes.

These changes have been of interest to the Centers for Disease Control and Prevention, where further characterization showed reduced hemagglutinin inhibition titers in some isolates.



Future



Molecular Characterization

- → ID Tag (Luminex)
- Neuraminidase sequencing
 - Potential antiviral resistance characterization
- Hemagglutinin inhibition



Collaborators



Global Emerging Infections Surveillance and Response System (GEIS)

Naval Health Research Center (NHRC)

Armed Forces Research Institute for Medical Sciences (AFRIMS)

Naval Medical Research Center-Detachment (NMRC-D)

US Army Medical Research Unit-Kenya (USAMRU-K)

Center for Health Promotion and Preventive Medicine-West (CHPPM-W)

Health Affairs

Combatant Commands (COCOM)

Military Surveillance sites

Centers for Disease Control and Prevention (CDC)

World Health Organization (WHO)



AFIOH Contacts



E-mail: influenza@brooks.af.mil

Phone Contact

Epidemiology: (210) 536-3471; DSN 240

Laboratory: (210) 536-1679; DSN 240

Website:

https://gumbo.brooks.af.mil/pestilence/Influenza/